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H I G H L I G H T S
• Higher expression of the active form of Src (pTyr418) in obese patients platelets.• Increased aggregation levels of obese platelets in response to GPVI activation.• GPVI-activated platelets show higher levels of tyr-phosphorylated PLCγ2 in obesity.• Higher surface expression levels of GPVI in obese platelets, correlating with BMI.








A B S T R A C T
Background and aims: Platelets play a fundamental role in the increased atherothrombotic risk related to central
obesity since they show hyperactivation and lower sensitivity to antiplatelet therapy in obese patients. The main
goal of this study was to identify platelet biomarkers related to the risk of atherothrombosis in obese patients,
confirm platelet activation levels in these patients, and identify altered activation pathways.
Methods: Platelets were obtained from cohorts of obese patients and age- and sex-matched lean controls.
Biochemical and proteome analyses were done by two-dimensional differential in-gel electrophoresis (2D-DIGE),
mass spectrometry, and immunoblotting. Functional and mechanistic studies were conducted with aggregation
assays and flow cytometry.
Results: We confirmed an up-regulation of αIIb and fibrinogen isoforms in platelets from obese patients. A
complementary platelet aggregation approach showed platelets from obese patients are hyper-reactive in re-
sponse to collagen and collagen-related peptide (CRP), revealing the collagen receptor Glycoprotein VI (GPVI)
signalling as one of the altered pathways. We also found the active form of Src (pTyr418) is up-regulated in
platelets from obese individuals, which links proteomics to aggregation data. Moreover, we showed that CRP-
activated platelets present higher levels of tyrosine phosphorylated PLCγ2 in obese patients, confirming al-
terations in GPVI signalling. In line with the above, flow cytometry studies show higher surface expression levels
of total GPVI and GPVI-dimer in obese platelets, both correlating with BMI.
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T
Conclusions: Our results suggest a higher activation state of SFKs-mediated signalling pathways in platelets from
obese patients, with a primary involvement of GPVI signalling.
1. Introduction
Obesity represents one of the biggest health problems in in-
dustrialized countries. Indeed, the World Health Organization estimates
that more than 1 billion adults worldwide are overweight, 300 million
of whom are clinically obese (defined as having a body mass index
(BMI) ≥30 kg/m2) [1].
Central obesity corresponds to an excess of intra-abdominal adipose
tissue [2]. This accumulation leads to the intrinsic dysfunction of adi-
pose tissue, together with insulin resistance, endothelial dysfunction,
systemic inflammatory state and oxidative stress. It is well known that
those obesity-associated alterations constitute a relevant risk factor for
suffering cardiovascular diseases (CVD), especially, the development of
atherothrombosis [3]. In fact, the link between obesity and CVD has
been repeatedly evidenced and associated with the chronic exposure to
a pro-inflammatory and pro-thrombotic state in obese subjects [4].
Obese individuals tend to have platelet abnormalities in mean pla-
telet volume and higher rates of ischemic events [5,6]. Increased pla-
telet activation has been found in obese women free of cardiovascular
risk factors [7]. Furthermore, recent studies focused the attention on
the pathogenetic role of platelet hyperactivation and reduced sensi-
tivity to antiaggregating therapy in obese patients [4,8].
The main goal of the present study was to identify platelet biomarkers
related to the risk atherothrombosis in obese patients without CVD. Initial
proteomic results were validated by immunoblotting on larger cohorts of
patients. Moreover, complementary flow cytometry (FACs) and aggrega-
tion studies were undertaken to confirm platelet activation levels on these
patients, and identify the most altered activation pathways.
2. Materials and methods
2.1. Patients
The study was approved by the Galician Investigation Ethics
Committee and followed the Declaration of Helsinki principles. All
participants provided written informed consent.
Thirty-four patients referred to the Endocrinology Unit at the
Santiago de Compostela University Hospital, Spain, participated in the
study. These patients had a BMI higher than 40, indicating severe
“healthy” obesity, and were referred to the hospital by the primary care
physician so they could be treated by an endocrinologist. Exclusion
criteria were coagulation disorders, platelet-associated disorders,
chronic antiplatelet drugs and other chronic drug therapy (except for
drugs required to treat pre-existing clinical factors that do not affect
platelet reactivity). Only 1 patient was diabetic, with no relevant im-
pact on the results; this patient was included in the pooled samples but
not in any individual validation approach. The lean control group
consisted of healthy normal weight volunteers recruited at the Santiago
de Compostela University Health Service. This group was age- and
gender-matched with the obese group and individuals had a BMI be-
tween 18 and 26.
Additionally, another group of 11 healthy volunteers with BMI be-
tween 26 and 35 (overweight and grade 1 obese individuals) was in-
cluded to investigate the expression levels of GPVI on the platelet
surface. This group, age-matched with the other groups, was also re-
cruited at the Santiago de Compostela University Health Service.
The initial proteomic screening included 10 obese patients and 10
lean matched-controls (Supplementary Table 1). Immunoblotting vali-
dations and functional studies included 34 obese patients and 34 lean
controls (Supplementary Table 2).
2.2. Platelet isolation and aggregation
Fresh blood samples (36mL) were collected from obese patients and
lean matched-controls in coagulation 3.2% sodium citrate Vacuette®
tubes and processed in less than 60min. In order to obtain the platelet-
rich plasma (PRP), blood was centrifuged for 20min at 200 g at room
temperature.
Washed platelets were isolated following a well-defined protocol
that limits blood cells or plasma proteins contaminations [9]. Final
washed platelet pellets were resuspended in HEPES-Tyrodes
(134mmol/L NaCl, 0.34mmol/L Na2HPO4, 2.9 mmol/L KCl, 12mmol/
L NaHCO3, 20mmol/L HEPES, 5mmol/L glucose, 1 mmol/L MgCl2, pH
7.3) and allowed to rest for 30min at room temperature.
For proteomic studies based on two-dimensional differential gel
electrophoresis (2D-DIGE), concentrations of 8× 108 platelets/mL
were lysed in a previously described NP-40-based lysis buffer and
stored at −80 °C [10].
PRP or washed platelets (2.5× 108 platelets/mL in HEPES-Tyrodes)
were used for aggregation studies. Aggregations were performed with
300 μL aliquots of PRP or washed platelets that were warmed at 37 °C
for 4min without stirring and for 1min with constant stirring at
1200 rpm in a Chrono-log aggregometer, before stimulation with the
corresponding agonists for 6min.
In the case of PRP, stimulations were done with collagen-related
peptide (CRP)-XL (0.1, 0.15 and 0.2 μg/mL), Horm collagen (0.5, 0.75
and 1 μg/mL), rhodocytin (25 and 50 nM), ADP (2 and 3 μM) and ara-
chidonic acid (0.3 and 0.5 mM). Washed platelets were activated with
collagen-related peptide (CRP)-XL (0.4, 0.5 and 1 μg/mL), Horm col-
lagen (1, 2 and 3 μg/mL), rhodocytin (25, 50 and 100 nM) and
thrombin (0.5 and 0.75 U/mL). Detailed information on the sources of
agonists can be found in the Supplementary Materials.
2.3. 2D-DIGE
For proteomic analysis, proteins were precipitated in 20% tri-
chloroacetic acid in acetone, as previously described [9]. Protein pellets
were resuspended in 60 μL DIGE buffer (65mM CHAPS, 5M urea, 2M
thiourea, 0.15M NDSB-256, 30mM Tris, 1 mM sodium vanadate,
0.1 mM sodium fluoride, and 1mM benzamidine). Protein quantitation
was done with Coomassie Plus protein reagent (Thermo Scientific).
Six gels (technical replicates) were run in the experiment with a total of
150 μg of mixed labeled protein per gel. These protein mixtures contained
50 μg of protein from each sample (10 obese pooled and 10 lean pooled
matched-controls) randomly labeled with 400 pmol minimal CyDye DIGE
fluors (Cy3 and Cy5), and 50 μg of a pool of both conditions (25 μg from
obese patients and 25 μg from lean controls) labeled with 400 pmol Cy2
(internal standard). Electrophoresis was done as indicated in the
Supplementary Material. The first dimension was on immobilized pH
gradient (IPG) strips 4–7, 24 cm (GE Healthcare). The second dimension
was on 11% SDS-polyacrylamide gels. Following electrophoresis, gels were
scanned directly in a Typhoon FLA 7000 scanner (GE Healthcare). Scanned
images were processed with Progenesis SameSpots software (v 4.5) from
Nonlinear Dynamics Ltd. (Newcastle, UK) in order to find real differences
between conditions. Further information on the 2D-DIGE and image ana-
lysis protocols can be found in the Supplementary Materials.
2.4. Mass spectrometric analysis
Spots of interest were excised manually from the gels and in-gel di-
gested with trypsin as previously indicated [11]. Most of the
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identifications were by LC–MS/MS on an EASY-nLC (Proxeon, Bruker
Daltonics) and a Bruker Amazon ETD ion trap. Remaining identifications
were by MALDI-TOF(/TOF), in a 4800 Plus MALDI-TOF/TOF analyzer
(Applied Biosystems). Database search was performed with the Mascot
Version 2.3.0 search tool (Matrix Science, London, United Kingdom)
screening SwissProt. Precise details on the MS protocols and database
searching parameters can be found in the Supplementary Methods.
2.5. Systems biology
Ingenuity Pathways Analysis (IPA) software (Ingenuity Systems, CA,
USA) was used to investigate possible interactions among all the
identified proteins. STRING v10 software [12] was also used to
predicted protein-protein interactions and to know the biological pro-
cess, molecular functions and cellular components where the differ-
ential proteins were involved.
2.6. Western blotting
Western blotting was performed to analyze individual samples
(biological replicates) for validation purposes. 11% SDS-PAGE gels
were used, loading 10 μg of protein per lane. In some cases, 2D-western
blotting validations were carried out, using IPG strips pI 4–7, 7 cm (GE
Healthcare). In that case, 30 μg of protein were loaded per strip; obese
and lean samples were analyzed in parallel. IEF (first dimension) was
for 11Kvh; second dimension was on 11% SDS-PAGE gels.
Fig. 1. 2D-DIGE-based differential proteome analysis of platelets from obese and lean individuals: up-regulation of fibrinogen features in obese patients.
(A-i) Representative image of the analysis in grey scale. The figure shows the location on the 2D gels of those spots that are differentially regulated when comparing
obese patients and lean matched-controls. Protein identifications are shown by the identification numbers in Supplementary Tables 3 and 4. Spots corresponding to
fibrinogen are indicated with a black arrow. (A-ii) Enlarged images of representative fibrinogen spots found to be up-regulated in obese patients by proteomics. (B)
Representative 2D-Western blot images of fibrinogen on pools of samples from obese-patients’ platelets and lean matched-controls (n=22 per group). GAPDH was
used as loading control (1D-western blot). Western blot experiments were run in triplicate. OB: severe obese patients; C: lean matched-controls; IB: immunoblot.
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Following electrophoresis, proteins were transferred onto poly-
vinylidene difluoride (PVDF) membranes. Membranes were blocked in
5% BSA in TBS-T (20mM Tris-HCl, (pH 7.6), 150mM NaCl and 0.1%
Tween 20) overnight at 4 °C and incubated for 90min at room tem-
perature with the following primary antibodies: rabbit anti-phospho-
SRC (Tyr418) (Invitrogen), dilution 1:1000; rabbit anti-SRC pan
(Invitrogen), dilution 1:1000; mouse anti-FIB (sc-69775, Santa Cruz),
dilution 1:1000; mouse anti-PLCγ2 (sc-5283, Santa Cruz), dilution
1:1000; rabbit anti-GAPDH (SIGMA), dilution 1:5000; and anti-G6f
(1:1000), produced by CovalAB UK (Cambridge, UK). Following washes
in TBS-T, membranes were exposed to horseradish peroxidase–labeled
goat anti-rabbit, or goat anti-mouse antibodies (dilution 1:5000)
(Pierce, Rockford, IL), and processed using an enhanced-chemilumi-
niscence system (ECL, Pierce, Rockford, USA).
2.7. Immunoprecipitation
Basal and activated platelets (8× 108platelets/mL, 500 μL per im-
munoprecipitation; activations with CRP-XL 1 μg/mL, 90sec) were
lysed with NP40-based lysis buffer, as indicated in Supplementary
Material. Activations were under non-aggregating conditions in the
presence of integrilin (9 μM). Phosphotyrosine (p-Tyr) im-
munoprecipitations were done with 5 μg of agarose-conjugated 4G10
monoclonal anti-phosphotyrosine antibody (EMD Millipore
Corporation, Billerica, MA, USA) per sample, as previously shown [13].
Further details on the protocol can be found in Supplementary Material.
Immunoprecipitations from twelve obese patients and ten lean
matched-controls were loaded independently, and proteins resolved on
4–12% NuPAGE Bis-Tris gradient gels (Invitrogen, Carlsbad, CA, USA).
Following the electrophoresis, proteins were transferred onto poly-
vinylidene difluoride (PVDF) membranes (GE Healthcare) and in-
cubated with primary antibodies (PLCγ2 and G6F) as describe above.
2.8. Flow cytometry
To measure GPVI dimer, GPVI total and P-selectin, 10 μL of platelet
solution, either 5-fold diluted whole blood or washed platelets
(5× 107 cells/mL), was mixed with 10 μL of 204-11 Fab (GPVI-dimer-
specific; 5 μg/mL, final), 1G5 (pan GPVI; 10 μg/mL, final) (Biocytex,
France) and CD62 (10 μg/mL, final) (ABCAM, UK) and incubated for
10min. For all of them, ALEXA 488 anti-mouse F(ab)2 antibody (50 μg/
mL, final) (Jackson ImmunoResearch) was added as the secondary
antibody and incubated for 10min. In individual Eppendorf tubes each
reaction mixture was diluted with 0.200mL of diluent (Beckman
Coulter, USA), and then antibody binding was measured by an Accuri
C6 flow cytometer (BD Biosciences). Platelet binding to appropriate
controls, mouse Fab (Jackson ImmunoResearch) when the primary
antibody was 204-11 Fab, IgG2A when it was 1G5 and IgG1 when it
was CD62, was determined. The test was run in triplicate and the
average of mean fluorescence intensity was measured.
2.9. Statistical analysis
Categorical variables from obese patients and lean matched-controls
are expressed as percentages and were compared using the Fisher exact
test. Continuous variables are expressed as the median ± SD, and were
compared by the Mann-Whitney test. Correlations analyses were done
using the Spearman's test.
As indicated above, the differential proteomic analysis was done
analyzing all the spots between obese patients and lean matched-con-
trols; for a given spot, the probability value was calculated using the
quantified and normalized volumes for the matched spot. All prob-
ability values were calculated using 1-way ANOVA analysis and values
of p < 0.05 were considered statistically significant.
For 1D-western blotting validation studies, protein bands intensity
was quantified by densitometry using ImageJ (National Institute of
Health, Bethesda, MD, USA) version 1.47. All analyses were performed




Thirty-four patients admitted to the hospital with a diagnosis of
severe “healthy” obesity (BMI≥40) and 34 age- and gender-matched
lean healthy controls were included in the study (Supplementary
Table 2). From those, a cohort of 10 obese patients and 10 matched-
controls were included in the proteomic analysis (Supplementary
Table 1), with only 1 diabetic patient. Apart from the diabetic patient,
HBA1c levels were within the normal range (below 6.5%).
Significant clinical differences between groups were observed in the
BMI and leukocytes count parameters, as expected. Unexpectedly, there
was also an increase in MPV in the lean group, when analyzing all
patients without subgroup divisions, although all values fell within the
normal physiological range (Supplementary Table 2).
3.2. Differential platelet proteome analysis: most up-regulated proteins from
obese patients are related to platelet activation and aggregation
The 2D-DIGE-based proteomic analysis focussed on the pI 4-7 range,
where most of the platelet proteome is located [14]. In total, 1895
protein spots were detected per gel, 55 of which were differentially
regulated between obese and lean groups (fold change cut-off≥1.2;
p < 0.05) (Fig. 1A). Out of those 55 differences, 25 were up-regulated
in obese patients whereas 30 were down-regulated. A principal com-
ponents analysis (PCA) showed a very good separation between groups
based on the proteome profile (data not shown). We could successfully
identify 35 protein features by MS which corresponded to 33 different
ORFs (Supplementary Tables 3 and 4).
Regarding protein function, 17 of the identified proteins play an
important role in stress response, including oxidative stress (e.g. heat
shock protein beta-1) and inflammatory response (e.g. zyxin and lyso-
zyme C). Another important group represented is related to main-
tenance of hemostasis, platelet aggregation and degranulation (e.g.
integrin αIIb, fibrinogen). In fact, STRING v10.5 software [12] in-
dicated that 50% of the obese up-regulated proteins are involved in
platelet activation and aggregation (e.g. actin, actinin-1, fibrinogen,
thrombospondin-1 (TSP1), integrin αIIb). Moreover, Ingenuity Path-
ways Analysis software (IPA, Ingenuity Systems, www.ingenuity.com)
identified integrin signalling as the most affected pathway related to the
proteins identified. In addition, the top molecular and cellular functions
related to the differentially regulated proteins identified are aggrega-
tion of blood platelets and thrombus formation. Moreover, most of the
altered proteins identified are part of a common network related to cell-
to-cell signaling, hematological system development and function, and
inflammatory response (Supplementary Fig. 1).
One of the proteins up-regulated in platelets from obese patients
was fibrinogen, previously reported in the platelet proteome [14]. Our
proteomic analysis showed the presence of this protein in 7 differen-
tially regulated spots: two of them corresponded to the β-chain and 5 to
the γ-chain. All of these spots were found to be up-regulated in platelets
from obese patients. Fibrinogen levels were validated by 2D Western
blotting on pools (22 severe obese patients and 22 lean controls). In line
with the proteomics results, a series of fibrinogen spots appear up-
regulated in obese patients’ samples (Fig. 1B).
3.3. Platelet aggregation in response to GPVI stimulation is increased in
obese patients compared to lean matched-controls
In parallel to the proteomic studies, we carried out platelet ag-
gregation-based functional analysis.
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Platelets were activated with various agonists: GPVI ligands, such
as, CRP-XL and collagen at different doses and conditions (PRP and
washed platelets), rhodocytin, arachidonic acid, ADP and thrombin
(Supplementary Tables 5 and 6).
Platelet aggregation following activation of GPVI was higher in se-
vere obese patients. As expected, there were certain differences among
conditions (PRP or washed platelets) (Fig. 2).
However, no significant differences in platelet aggregation between
obese and lean matched-controls were observed following activation
with rhodocytin (CLEC-2 agonist); or with non-SFKs-mediated signal-
ling pathways agonists, such as ADP, arachidonic acid and thrombin
(Supplementary Fig. 2).
These aggregation studies showed that obese platelets are hyper-
reactive in response to collagen and CRP, pointing towards GPVI sig-
nalling as one of the altered pathways in obesity.
3.4. Active Src (pTyr418) is up-regulated in platelets from obese patients
The proteomic identification of up-regulated proteins such as in-
tegrin αIIb, fibrinogen, actinin 1 and vinculin and the hyper-reactiva-
tion of platelets in response to CRP-XL and collagen in obese patients
points towards a possible alteration of SFKs-mediated pathways.
Src is a 60-kDa nonreceptor tyrosine kinase involved in transmitting
activation signals from a diverse repertoire of platelet surface receptors,
including integrin αIIbβ3, the immunoreceptor tyrosine–based activa-
tion motif–containing collagen receptor complex Glycoprotein VI
(GPVI)-FcRγ-chain, and the von Willebrand factor receptor complex
GPIb-IX-V, which are essential for thrombus growth and stability [15].
Src and other members of the SFKs are tightly regulated by tyrosine
phosphorylation. Full catalytic activity of Src requires phosphorylation
of tyrosine 418, which is located in the catalytic domain. By using a
specific anti-Src (pTyr418) antibody, we demonstrated that the active
form of Src is up-regulated in platelets from a cohort of 29 “healthy”
obese patients with BMI≥ 40 compared to matched lean healthy con-
trols (Fig. 3).
3.5. PLCγ2 is hyper-phosphorylated in platelets from obese patients
following CRP-XL stimulation
To complement the data shown above, we analyzed a sub-group of
patients to clarify alterations in GPVI signalling following CRP-XL sti-
mulation. We chose PLCγ2 as a key protein in GPVI signalling that we
previously observed to be altered following CRP-XL stimulation in
platelets from ST-elevation myocardial infarction (STEMI) patients
[13]. After immunoprecipitation with the 4G10 antiphosphotyrosine
antibody, we saw an increase of PLCγ2 tyr phosphorylation in the obese
group compared to lean matched-controls, which suggests a hyper-
activation of GPVI signalling in line with the results shown above
(Fig. 4).
However, we found no significant differences in G6F, as opposed to
the STEMI study [13] (data not shown).
3.6. Higher expression levels of total GPVI and GPVI dimer in the surface of
platelet from obese patients
Flow cytometry was used to mechanistically understand the ag-
gregation and biochemical data that pointed towards alterations in
GPVI signalling in obese patients. For that reason, we analyzed the
expression of GPVI in whole blood from 12 “healthy” severe obese and
12 lean matched-controls. By using specific antibodies, we studied the
platelet surface expressions levels of total GPVI and the dimer form
(GPVI-dimer) [16]. We demonstrated higher expression levels of both
of them in obese patients, which could explain the observed hyper-
activation of GPVI signalling (Fig. 5A). In addition, we found a positive
Fig. 2. Platelet aggregation in response to GPVI
activation is increased in obese patients compared
to lean matched-controls.
PRP and washed platelets were stimulated with
different GPVI agonists. (A) PRP was stimulated
with CRP-XL (0.1, 0.15 or 0.2 μg/mL) or Horm
collagen (0.5, 0.75 or 1 μg/mL) to trigger ag-
gregation. (B) Washed platelets were stimulated
with CRP-XL (0.4, 0.5 or 1 μg/mL) and Horm col-
lagen (1, 2 or 3 μg/mL). Results are presented as
the mean ± SD; *p < 0.05, **p < 0.01,
***p < 0.001. p-values and cohort data are shown
in Supplementary Table 5. OB: severe obese pa-
tients; C: lean-matched controls.
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correlation between total GPVI, GPVI-dimer and BMI in all participants,
of the study (Fig. 5B). Additionally, we investigated another group of 11
healthy individuals with BMI between 26 and 35 (overweight and grade
I obesity). Interestingly, we also found higher expression levels of GPVI
(total and dimer) in this group compared to lean individuals
(Supplementary Fig. 3A). When integrating these data with those ob-
tained for severe obese patients (Fig. 5), the positive correlation with
BMI is maintained (Supplementary Fig. 3B).
Finally, no significant differences between severe obese patients and
lean matched-controls were found when levels of p-selectin were
measured in washed platelets although there is a tendency to increased
levels in the obese group (not shown).
4. Discussion
The principal findings of the present study are: (i) proteomics al-
terations in proteins related to platelet signalling - including integrin
signalling - in obese patients together with increased levels of fi-
brinogen, the latter validated by immunoblotting; (ii) the identification
of increased aggregation levels of platelets from obese patients in re-
sponse to CRP-XL and Horm collagen, pointing towards GPVI signalling
as one of the altered pathways in obesity; (iii) there is a higher
expression of the active form of Src (pTyr418) – essential for GPVI and
integrin signalling - in platelets from obese patients compared to lean
individuals, linking proteomic and aggregation data; (iv) CRP-activated
platelets present higher levels of tyrosine phosphorylated PLCγ2 in
obese patients, which is in agreement with the previous data; (v) flow
cytometry results show higher surface expression levels of total GPVI
and GPVI-dimer in platelets from obese patients correlating positively
with the BMI; this latter point provides a mechanistic explanation for
the GPVI signalling data.
Focusing on the proteomic analysis, most of the proteins identified
in the present study are interconnected in a common network that
primarily involves integrin and actin cytoskeleton signalling, processes
closely related to platelet aggregation and activation. Moreover,
Ingenuity Pathways Analysis software revealed inflammatory response,
thrombosis, and CVD as the most affected diseases related to the dif-
ferentially regulated proteins identified.
It is noteworthy that some of the proteins identified such as TSP1
and fibrinogen were previously found to be involved in obesity
[17–20]. TSP1 is a major component of platelet alpha granules al-
though it exists as both a component of the extracellular matrix and as a
soluble molecule found in various body fluids [19]. In fact, TSP1 has
recently been highlighted as a potential mediator of insulin resistance
Fig. 3. P-Src (pTyr 418) levels are augmented in
platelets from obese patients.
(A) 1D-Western blot analysis of Src-pTyr418, Src
pan and GAPDH protein expression levels in pla-
telets from individual samples (29 obese patients
and 29 lean matched-controls). Images are re-
presentative of the results obtained and show
samples distributed in two gels. (B) Densitometry
graphs showing the mean values ± SD of Src (Tyr
418) of 30 obese patients and their lean matched-
controls corrected by Src and the loading control
(GAPDH), p-values are 0.037 and 0.024 respec-
tively. Moreover, densitometry graph showing the
mean values ± SD of Src corrected by the loading
control (GAPDH) indicates no differences between
obese and control groups (p-value = 0.97). OB:
severe obese patients; C: lean matched-controls; IB:
immunoblot; *p < 0.05.
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and adipose inflammation in obesity [18].
In relation to fibrinogen, we focused on this protein for validation
studies because it is highly represented in the analysis and has been
described as a potential biomarker for obesity and CVD [20,21]. Fi-
brinogen is a precursor of the clot structural protein fibrin. It has a
multimeric structure consisting of α, β and γ polypeptides. Two of these
polypeptides (β and γ) were detected in the present study. The γ chain is
of particular interest because it contains multiple epitopes that interact
with integrins, and plays a critical role in platelet aggregation and in-
flammation [22]. In fact, higher levels of fibrinogen γ have been re-
peatedly reported in CVD and obesity [23–25].
We identified the γ-isoform in 5 spots that were all up-regulated in
obese patients. This result was confirmed by western blotting. The up-
regulation of fibrinogen in obese platelets is consistent with the in-
creased levels previously found at circulating level in obese patients
[26,27] which could promote a hype-reactive state of different signal-
ling pathways such as those related to integrin αIIbβ3. Moreover, a
recent study with mice carrying genetically imposed deficiencies or
functional mutations in fibrinogen showed that fibrinogen drives high-
fat diet-induced obesity. This study concludes that the thrombin/fibrin
(ogen) axis is not only a critical trigger of high fat diet-mediated sys-
temic inflammation, but a pharmacologically and genetically adjustable
driver of obesity [28]. In addition, it is also relevant to point out that
GPVI was recently reported as a fibrin and fibrinogen receptor [29–31].
All the above data is consistent with the potential alterations in integrin
αIIbβ3 and GPVI signalling identified in the present study.
GPVI and αIIbβ3 platelet stimulation leads to activation of Src
through autophosphorylation at position Tyr418 [14,32]. Interestingly,
we demonstrate that the active form of Src (pTyr418) is up-regulated in
platelets from obese patients, suggesting a potential hyperactivation
state of those pathways, such as GPVI, where SFKs are essential. In line
with the latter, we also showed that PLCγ2, a key protein of the sig-
nalling pathway, was hyper-phosphorylated in the obese group fol-
lowing CRP-XL platelet stimulation. This suggests a higher activated
state of GPVI signalling in obese patients, as we previously reported for
STEMI patients [13].
Additionally, our aggregation assays provided further evidence that
there is an alteration of GPVI signalling in platelets from obese patients.
Platelets from the obese individuals showed enhanced aggregation in
response to collagen and the GPVI-specific agonist CRP-XL compared to
lean matched-controls, suggesting a higher activation of this signalling
pathway in obese patients. Aggregation data are in line with the bio-
chemical results shown above.
There are various explanations for the GPVI signalling data dis-
cussed above. High levels of fibrinogen in plasma could interact with
GPVI receptor enhancing the pathway activation [33]. However, an-
other possibility for our results could be increased surface expression
levels of platelet GPVI (total or the dimeric form) in obese patients as it
has already been shown in other diseases such as ischemic stroke
[31,34]. Both possibilities could co-exist.
To clarify the results mechanistically, we performed a FACs assay
where we demonstrated higher expression levels of the dimer form of
GPVI and total GPVI in obese patients, which must be directly linked to
the higher activation levels of GPVI signalling and GPVI-mediated ag-
gregation observed in obese patients.
Finally, it is necessary to point out that this is a complex study and is
not free of some limitations: firstly, sample limitation was an issue,
somehow unavoidable when dealing with clinical samples; this was the
reason for pooling samples for the 2D-DIGE-proteomics and 2D-western
blotting analyses. Secondly, the variety of participants and where they
could be recruited (severe obese patients at the hospital, overweight
and lean volunteers at the Universidade de Santiago Health Service)
made difficult to obtain the same clinical-biochemical parameters for
all of them; nevertheless, the most relevant ones could be obtained and
shown in the clinical tables.
In conclusion, the present study is the first to analyze in detail the
platelet proteome of obese patients. It provides novel information on
platelet proteome changes related to obesity and, in combination with
functional and biochemical assays, highlights those platelet signalling
pathways altered with higher probability in this pathology, such as SFK-
mediated pathways. Fibrinogen and the active form of the tyrosine ki-
nase Src were found to be up-regulated in platelets from obese patients.
Moreover, we show an up-regulation of GPVI signalling and GPVI
platelet surface expression in obese patients. Our results suggest that
obese patients present an atherothrombotic risk that should be con-
sidered, and highlight the relevance of considering novel antith-
rombotic drug targets in these patients, such as GPVI. We hope that our
study will open new lines of investigation to further explore the pa-
thophysiological role of platelets in obesity and find novel therapeutic
targets and platelet-related biomarkers for this type of patient.
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Fig. 4. PLCγ2 phosphorylation levels are increased in platelets from obese pa-
tients following CRP-XL stimulation.
Immunoblot analysis of PLCɣ2 following immunoprecipitation with the anti-
phosphorylation 4G10 mAB. Severe obese and lean matched controls are
compared using 4×108 platelets per immunoprecipitation. All samples were
stimulated with CRP (1 μg/mL; 90 s), as indicated in the Methods section. (A)
Representative images corresponding to individual patients are shown. Samples
were distributed in two gels; a vertical line indicates a failed well. (B)
Densitometry graph showing the mean values ± SD for all patients (severe
obese: 12; lean matched controls: 10). Significant differences are indicated:
***p < 0.0001. IP: immunoprecipitation; IB: immunoblot.
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